Small Molecule Injectable Drugs Market to Surpass US$ 347.0 Billion by 2030 - Coherent Market Insights

SEATTLE, June 9, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global small molecule injectable drugs market is estimated to be valued at US$ 188.9 Billion in 2022 and is expected to exhibit a CAGR of 7.9% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Small Molecule Injectable Drugs Market:

Key trends in market include increasing product approvals, increasing prevalence of chronic pain, expansion of manufacturing facilities, and inorganic growth activities such as collaborations, etc.

Market players are involved in inorganic activities, such as collaborations, which will support expansion of product portfolio, and is further expected to drive growth of the global small molecule injectable drugs market, over the forecast period. For instance, in February 2022, Remix Therapeutics, a biotechnology company developing small molecule therapies to reprogram RNA (Ribonucleic acid) processing, announced a strategic collaboration with Janssen Pharmaceuticals, Inc., one of Johnson & Johnson's subsidiary to discover and develop small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.

Market players are also involved in launching new products i.e. small molecule injectable drugs, in order to expand their product portfolio, which is expected to drive growth of the market over the forecast period. For instance, in May 2021, Dr. Reddy's Laboratories Ltd., launched Ertapenem injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ, a medication approved by the U.S. Food and Drug Administration (U.S. FDA). Ertapenem is a carbapenem antibiotic that comes in the form of infusions or injections and is used to treat infections of the abdomen, lungs, upper part of the female reproductive system, and diabetic foot.

Moreover, key players are focused on expansion of their manufacturing facilities, for increase in production of small molecule injectable drugs. This is expected to fuel growth of the small molecule injectable drugs market, over the forecast period. For instance, in the year 2021, Fresenius Kabi AG, announced that they are expanding their facilities in Australia, in which the company will invest US$ 63.2 million till the end of the year 2023. The site will have special expertise in aseptic production and manufacturing of complex products such as analgesics, anesthetics, antibiotics, and anti-infectives.

Request for Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/5033

Key Market Takeaways:

Market players are engaged in inorganic activities such as partnerships, and this is expected to drive growth of the global small molecule injectable drugs market, over the forecast period. For instance, in March 2022, LifeMine Therapeutics, a biotechnology company based in the U.S., formed a research and development partnership with GlaxoSmithKline (GSK) to discover small molecule leads.

Among regions, North America is expected to hold a dominant position in the global small molecule injectable drugs market over the forecast period, owing to increasing prevalence of chronic pain in the region. For instance, according to the Centers for Disease Control and Prevention (CDC), 2021, it has been reported that around 50 million U.S. adults experience chronic pain.

Key players operating in the global small molecule injectable drugs market include Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd. AstraZeneca Plc, Baxter International Inc., Fresenius Kabi AG, Cipla Limited., Mylan N.V., GlaxoSmithKline Plc., Johnson & Johnson, Sanofi S.A., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG (Genentech, Inc.), Amgen, Inc., Gilead Sciences, Inc., and Hikma Pharmaceuticals plc.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/5033

Detailed Segmentation:

Global Small Molecule Injectable Drugs Market, By Drug Class:

• Chemotherapy
• Small Molecule Antibiotics
• Skeletal Muscle Relaxants
• Analgesics
• Anticoagulants
• Anticonvulsants
• Antivirals
• Others

Global Small Molecule Injectable Drugs Market, By Indication:

• Oncology
• Pain Management
• Cardiovascular Diseases
• Infectious Diseases
• CNS Diseases
• Others

Global Small Molecule Injectable Drugs Market, By Mode of Delivery:

• IV Set
• Infusion Pump
• Intravenous Injection
• Intramuscular Injection
• Subcutaneous Injection

Global Small Molecule Injectable Drugs Market, By End User:

• Hospitals
• Ambulatory Clinics
• Outpatient Facility
• Infusion Therapy Center
• Home Care
• Others

Global Small Molecule Injectable Drugs Market, By Region:

• North America
• By Country:
• U.S.
• Canada
• Europe
• By Country:
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country:
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
• By Country:
• GCC Countries
• Israel
• South Africa
• Rest of Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/5033 

Find related trending report below:

Brazil Injectable Drugs Market for Hospitals & Ambulatory Settings, by Product Type (Pre-filled syringes, Auto-injectors, Pre-filled Pens, Pre-mixed IV Bags, and Others), by Drug Class (Anesthesia, Antibiotics, Antidotes, Antiemetic, Anti-infective, Anti-Thrombolytic, Muscle Relaxant, Non Opioids, Opioids, Sedatives, and Others), and by Mode of Delivery (Intramuscular (IM), Intravenous (IV), Subcutaneous (SC), and Others (Epidural and Intrathecal) - Size, Share, Outlook, and Opportunity Analysis, 2022 – 2028

Middle East and Asia Injectable Drugs Market, by Product Type (Pre-filled Syringes, Auto-injectors, Pre-filled Pens, Pre-mixed IV Bags, and Others), by Drug Class (Anesthesia, Antibiotics, Antidotes, Antiemetic, Anti-infective, Anti-thrombolytic, Muscle Relaxant, Non Opioids, Opioids, Sedatives, and Others), by Route of Administration (Intramuscular (IM), Intravenous (IV), Subcutaneous (SC), and Others (Epidural and Intrathecal)), and by End Users (Hospitals, Clinics, and Ambulatory Surgery Centers) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:

Mr. Shah 
Senior Client Partner – Business Development 
Coherent Market Insights 
Phone:
US: +1-206-701-6702 
UK: +44-020-8133-4027
India: +91-848-285-0837 
Email: sales@coherentmarketinsights.com  
Website: https://www.coherentmarketinsights.com 
Follow Us: LinkedIn | Twitter 

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg